Arrayit Corporation (ARYC) 0.1450 $ARYC
Arrayit Corporation Showcases High Sensitivity Diagnostic Microarray Technology at 21st International Molecular Medicine Tri-Conference
GlobeNewswire - Mon Feb 10, 12:09PM CST
Arrayit Corporation (OTCBB:ARYC), a life sciences and molecular diagnostics leader, is showcasing its high sensitivity, high specificity patented and proprietary microarray platform at the 21 International Molecular Medicine Tri-Conference in San Francisco, CA, USA on February 9-14, 2014. The conference, which features more than 3,000 researchers and clinicians from 35 countries, focuses on drug discovery, genomics, diagnostics and information technology.
Genentech Purchases Arrayit Technology
PR Newswire - Tue Sep 10, 7:29AM CDT
Arrayit Corporation (OTCQB: ARYC) reports that pharmaceutical giant Genentech has purchased Arrayit's patented technology to accelerate drug discovery.
Arrayit on Major Fundraising Drive
PR Newswire - Mon Sep 09, 7:38AM CDT
Listonstreetpulse.com announces that Arrayit Corporation (OTC: ARYC) has been approached, through their financial advisor, who is a major shareholder in the company, by an overseas bank, and 3 mid-level investment banking houses, to help Arrayit raise up to $10 million in funds, either through a secured loan, or a convertible bond issue, with the conversion above 100% of the current stock price.
Arrayit Corporation Holds Successful Meeting with DHK Medical Products CEO
PR Newswire - Tue Sep 03, 6:45AM CDT
Listonstreetpulse.com announces that Arrayit Corporation (OTC: ARYC) held a successful meeting with DHK Medical Products CEO in California. DHK Medical Products offers technologically advanced products and services for the healthcare sector in India.
OTC Daily Alert Stock Watch - Arrayit (OTCBB: ARYC)
WorldStockWire - Thu Aug 15, 8:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Global Personalized Medicine Diagnostics Market 2012-2016: AltheaDx Inc. Launches FLT3 Mutation Assay in October 2012
M2 - Tue Aug 06, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x63hs3/global) has announced the addition of the "Global Personalized Medicine Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Personalized Medicine Diagnostics market to grow at a CAGR of 4.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicine for treating cancer. The Global Personalized Medicine Diagnostics market has also been witnessing an increase in the number of industrial activities. However, the low awareness of personalized medicine diagnostics in developing countries could pose a challenge to the growth of this market. The key vendors dominating this space include Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMerieux SA, Illumina Inc., and Roche Holding AG. Commenting on the report, an analyst from the team said: One of the main trends witnessed in the Global Personalized Medicine Diagnostics market is the development of innovative tools and technologies. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Furthermore, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 to predict the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. According to the report, one of the main factors driving the market is the increasing demand for personalized medicine diagnostics for treatment of cancer. Hyperthermia is one of the treatments of cancer where the use of personalized medicines and diagnostics is considered depending on a patient's specific attributes. Methods of treatments such as hyperthermia and radiotherapy have already been proposed. Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries. Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Becton Dickinson and Company - bioMerieux SA - Illumina Inc. - Roche Holding AG. - 20/20 GeneSystems Inc. - Accumetrics Inc. - AdvanDx Inc. - Affymetrix Inc. - Almac Group Ltd. - AltheaDx Inc. - Ambry Genetics Corp. - Amgen Inc. - Arrayit Corp. - AssureRx Health Inc. - Autogenomics Inc. - BG Medicine Inc. - Biocare Medical LLC - Biocartis SA - Biocept Inc. - BioCurex Inc. - Biodesix Inc. - Bio-Reference Laboratories Inc. - CombiMatrix Corp. - Corgenix Medical Corp. - DxTerity Diagnostics Inc. - EnzoBiochem Inc. - Epigenomics AG - Euroimmun AG - GE Healthcare - Genomic Health Inc. - Interleukin Genetics Inc. - Johnson & Johnson - Knome Inc. - Lab21 Ltd. - Life Technologies Corp. - MDxHealth SA - Myriad Genetics Inc. - Nanosphere Inc. - Pathway Genomics Corp. - Power3 Medical Products Inc. - Quest Diagnostics Inc. - Response Genetics Inc. - Rosetta Genomics Ltd. - Sequenom Inc. - Trovagene Inc. - Vermillion Inc. - Viracor-IBT Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/x63hs3/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BRLI: 28.83 (-0.42), A: 53.05 (-0.95), ILMN: 184.82 (+5.27), VRML: 1.60 (+0.02), AFFX: 7.65 (-0.03), BGMD: 0.51 (+0.04), JNJ: 101.22 (+0.86), NSPH: 0.49 (-0.25), ABT: 41.59 (-0.80), MYGN: 37.60 (+0.92), RGDX: 0.68 (+0.09), CBMX: 1.46 (-0.02), AMGN: 143.64 (-0.45), BMY: 51.84 (-0.11), GSK: 44.41 (+0.78), GHDX: 32.71 (-1.05), SQNM: 3.04 (-0.23), DGX: 61.21 (+0.09)
Arrayit Corporation Signs Exclusive Distributorship Agreement With DHK Medical Products for Genome Testing in India
GlobeNewswire - Wed Jun 26, 11:35AM CDT
Arrayit Corporation (OTCQB:ARYC), a life sciences and diagnostics company, announced today that it has signed an exclusive three-year distributorship agreement with DHK Medical Products ("DHK"
of Chandigarh India to sell Arrayit genomic tests in India. DHK will offer Arrayit genomic testing services through a planned expanding national network of 800 American Medical Center (AMC) facilities in the future and staffed with medical doctors, nurses, pharmacists and other highly trained personnel. AMC facilities will provide walk-in medical services from 7 AM to 11 PM seven days a week to support the changing Indian culture, which is experiencing rapid industrialization and upward social mobility. India is the most populous democracy in the world, with more than 1.2 billion people including 400 million residents in the increasingly affluent Indian middle class.
Arrayit (ARYC) Turns a Page with First Quarter Profit
ACCESSWIRE - Mon May 20, 10:12AM CDT
Arrayit Corp. (OTC Markets: ARYC) reported revenues that jumped 66% to $942,916 during the first quarter, with net income that swung from a loss of $1,344,651 to a profit of $235,478 year over year. With rising revenues and sustainable operations, the company's management team has successfully executed on its promises to unlock long-term value for shareholders.
Arrayit (ARYC) Featured on PBS NOVA Series
ACCESSWIRE-TNW - Mon Apr 29, 12:51PM CDT
Arrayit Corporation (OTCQB: ARYC), a developer, manufacturer and marketer of life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide, has been a leader in the microarray market for some time, having been featured on popular documentaries like PBS' NOVA series.
SQNM: 3.04 (-0.23)
SECFilings.com Issues Media Update on Arrayit Corporation
PR Newswire - Thu Apr 11, 7:30AM CDT
SECFilings.com, a leading provider of SEC filings news and analysis, has issued a media update on Arrayit Corporation (OTCQB: ARYC), a leading developer of life science tools and systems for the analysis of genetic variation, biological function and diagnostics.
Stocks with Technologies that Address Rising Healthcare Costs
ACCESSWIRE-TNW - Wed Apr 10, 10:07AM CDT
U.S. healthcare costs are skyrocketing and it's no secret that it could bankrupt the country if left unchecked. Medical Payment Advisor Commission chairman Glenn Hackbarth warned lawmakers in March that "pressure on the federal budget would continue as Social Security, Medicare, Medicaid, other health insurance programs, and net interest are projected to account for more than 16% of GDP in 10 years, whereas total federal revenues have averaged just 18.5% of GDP over the past 40 years" - big problems, indeed.
Arrayit's Leadership Position in the $21B Global Life Sciences Market
ACCESSWIRE-TNW - Thu Mar 21, 11:06AM CDT
If the $21 billion global life sciences market is like a freight train, then microarrays can be thought of as the tracks. Microarrays are collections of microscopic DNA and protein spots attached to a solid surface that are used to simultaneously measure the expression levels of a large number of genes and proteins or to genotype multiple regions of a genome. Through this rapid analysis, microarrays have dramatically accelerated research involving the human genome and proteome.
MYGN: 37.60 (+0.92)
Arrayit's Potential as a Blockbuster Companion Diagnostic
ACCESSWIRE-TNW - Thu Mar 07, 8:06AM CST
The pharmaceutical industry can be a volatile place to invest, with share prices relying on successful clinical trials and ongoing regulatory compliance. In many cases, companies could reduce these risks by properly vetting clinical trial participants and patients in order to ensure that they are treating the right patients. The personalized medicine movement could help in this regard with the growing popularity of so-called companion diagnostics.
Could Arrayit's Early Ovarian Cancer Diagnostic Save 12,000 Lives a Year?
ACCESSWIRE-TNW - Tue Feb 19, 8:06AM CST
The biotechnology industry is as exciting in 2013 as it ever has been before, providing investors opportunities to be a part of a paradigm shift that exploits decades of research that are now cornerstones for building game-changing therapies. One of the most intriguing propositions today is that of genomics, an industry that is gaining traction in the medical space in recent years. Ten years after the completion of the Human Genome Project, the decreasing costs associated with mapping and molecular diagnostics are shepherding increasing acceptance and usage, uniquely positioning Arrayit Corporation (OTCQB: ARYC) for growth amid larger peers like Exact Sciences Corp. (NASDAQ: EXAS) and Myriad Genetics, Inc. (NASDAQ: MYGN), especially with Arrayit's focus on diagnostics for ovarian cancer as part of their larger portfolio of offerings.
MYGN: 37.60 (+0.92), EXAS: 23.43 (-0.79)
Arrayit Corporation Showcases High Sensitivity Diagnostic Microarray Technology at 21st International Molecular Medicine Tri-Conference
GlobeNewswire - Mon Feb 10, 12:09PM CST
Arrayit Corporation (OTCBB:ARYC), a life sciences and molecular diagnostics leader, is showcasing its high sensitivity, high specificity patented and proprietary microarray platform at the 21 International Molecular Medicine Tri-Conference in San Francisco, CA, USA on February 9-14, 2014. The conference, which features more than 3,000 researchers and clinicians from 35 countries, focuses on drug discovery, genomics, diagnostics and information technology.
Genentech Purchases Arrayit Technology
PR Newswire - Tue Sep 10, 7:29AM CDT
Arrayit Corporation (OTCQB: ARYC) reports that pharmaceutical giant Genentech has purchased Arrayit's patented technology to accelerate drug discovery.
Arrayit on Major Fundraising Drive
PR Newswire - Mon Sep 09, 7:38AM CDT
Listonstreetpulse.com announces that Arrayit Corporation (OTC: ARYC) has been approached, through their financial advisor, who is a major shareholder in the company, by an overseas bank, and 3 mid-level investment banking houses, to help Arrayit raise up to $10 million in funds, either through a secured loan, or a convertible bond issue, with the conversion above 100% of the current stock price.
Arrayit Corporation Holds Successful Meeting with DHK Medical Products CEO
PR Newswire - Tue Sep 03, 6:45AM CDT
Listonstreetpulse.com announces that Arrayit Corporation (OTC: ARYC) held a successful meeting with DHK Medical Products CEO in California. DHK Medical Products offers technologically advanced products and services for the healthcare sector in India.
OTC Daily Alert Stock Watch - Arrayit (OTCBB: ARYC)
WorldStockWire - Thu Aug 15, 8:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Global Personalized Medicine Diagnostics Market 2012-2016: AltheaDx Inc. Launches FLT3 Mutation Assay in October 2012
M2 - Tue Aug 06, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x63hs3/global) has announced the addition of the "Global Personalized Medicine Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Personalized Medicine Diagnostics market to grow at a CAGR of 4.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicine for treating cancer. The Global Personalized Medicine Diagnostics market has also been witnessing an increase in the number of industrial activities. However, the low awareness of personalized medicine diagnostics in developing countries could pose a challenge to the growth of this market. The key vendors dominating this space include Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMerieux SA, Illumina Inc., and Roche Holding AG. Commenting on the report, an analyst from the team said: One of the main trends witnessed in the Global Personalized Medicine Diagnostics market is the development of innovative tools and technologies. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Furthermore, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 to predict the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. According to the report, one of the main factors driving the market is the increasing demand for personalized medicine diagnostics for treatment of cancer. Hyperthermia is one of the treatments of cancer where the use of personalized medicines and diagnostics is considered depending on a patient's specific attributes. Methods of treatments such as hyperthermia and radiotherapy have already been proposed. Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries. Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Becton Dickinson and Company - bioMerieux SA - Illumina Inc. - Roche Holding AG. - 20/20 GeneSystems Inc. - Accumetrics Inc. - AdvanDx Inc. - Affymetrix Inc. - Almac Group Ltd. - AltheaDx Inc. - Ambry Genetics Corp. - Amgen Inc. - Arrayit Corp. - AssureRx Health Inc. - Autogenomics Inc. - BG Medicine Inc. - Biocare Medical LLC - Biocartis SA - Biocept Inc. - BioCurex Inc. - Biodesix Inc. - Bio-Reference Laboratories Inc. - CombiMatrix Corp. - Corgenix Medical Corp. - DxTerity Diagnostics Inc. - EnzoBiochem Inc. - Epigenomics AG - Euroimmun AG - GE Healthcare - Genomic Health Inc. - Interleukin Genetics Inc. - Johnson & Johnson - Knome Inc. - Lab21 Ltd. - Life Technologies Corp. - MDxHealth SA - Myriad Genetics Inc. - Nanosphere Inc. - Pathway Genomics Corp. - Power3 Medical Products Inc. - Quest Diagnostics Inc. - Response Genetics Inc. - Rosetta Genomics Ltd. - Sequenom Inc. - Trovagene Inc. - Vermillion Inc. - Viracor-IBT Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/x63hs3/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BRLI: 28.83 (-0.42), A: 53.05 (-0.95), ILMN: 184.82 (+5.27), VRML: 1.60 (+0.02), AFFX: 7.65 (-0.03), BGMD: 0.51 (+0.04), JNJ: 101.22 (+0.86), NSPH: 0.49 (-0.25), ABT: 41.59 (-0.80), MYGN: 37.60 (+0.92), RGDX: 0.68 (+0.09), CBMX: 1.46 (-0.02), AMGN: 143.64 (-0.45), BMY: 51.84 (-0.11), GSK: 44.41 (+0.78), GHDX: 32.71 (-1.05), SQNM: 3.04 (-0.23), DGX: 61.21 (+0.09)
Arrayit Corporation Signs Exclusive Distributorship Agreement With DHK Medical Products for Genome Testing in India
GlobeNewswire - Wed Jun 26, 11:35AM CDT
Arrayit Corporation (OTCQB:ARYC), a life sciences and diagnostics company, announced today that it has signed an exclusive three-year distributorship agreement with DHK Medical Products ("DHK"
of Chandigarh India to sell Arrayit genomic tests in India. DHK will offer Arrayit genomic testing services through a planned expanding national network of 800 American Medical Center (AMC) facilities in the future and staffed with medical doctors, nurses, pharmacists and other highly trained personnel. AMC facilities will provide walk-in medical services from 7 AM to 11 PM seven days a week to support the changing Indian culture, which is experiencing rapid industrialization and upward social mobility. India is the most populous democracy in the world, with more than 1.2 billion people including 400 million residents in the increasingly affluent Indian middle class. Arrayit (ARYC) Turns a Page with First Quarter Profit
ACCESSWIRE - Mon May 20, 10:12AM CDT
Arrayit Corp. (OTC Markets: ARYC) reported revenues that jumped 66% to $942,916 during the first quarter, with net income that swung from a loss of $1,344,651 to a profit of $235,478 year over year. With rising revenues and sustainable operations, the company's management team has successfully executed on its promises to unlock long-term value for shareholders.
Arrayit (ARYC) Featured on PBS NOVA Series
ACCESSWIRE-TNW - Mon Apr 29, 12:51PM CDT
Arrayit Corporation (OTCQB: ARYC), a developer, manufacturer and marketer of life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide, has been a leader in the microarray market for some time, having been featured on popular documentaries like PBS' NOVA series.
SQNM: 3.04 (-0.23)
SECFilings.com Issues Media Update on Arrayit Corporation
PR Newswire - Thu Apr 11, 7:30AM CDT
SECFilings.com, a leading provider of SEC filings news and analysis, has issued a media update on Arrayit Corporation (OTCQB: ARYC), a leading developer of life science tools and systems for the analysis of genetic variation, biological function and diagnostics.
Stocks with Technologies that Address Rising Healthcare Costs
ACCESSWIRE-TNW - Wed Apr 10, 10:07AM CDT
U.S. healthcare costs are skyrocketing and it's no secret that it could bankrupt the country if left unchecked. Medical Payment Advisor Commission chairman Glenn Hackbarth warned lawmakers in March that "pressure on the federal budget would continue as Social Security, Medicare, Medicaid, other health insurance programs, and net interest are projected to account for more than 16% of GDP in 10 years, whereas total federal revenues have averaged just 18.5% of GDP over the past 40 years" - big problems, indeed.
Arrayit's Leadership Position in the $21B Global Life Sciences Market
ACCESSWIRE-TNW - Thu Mar 21, 11:06AM CDT
If the $21 billion global life sciences market is like a freight train, then microarrays can be thought of as the tracks. Microarrays are collections of microscopic DNA and protein spots attached to a solid surface that are used to simultaneously measure the expression levels of a large number of genes and proteins or to genotype multiple regions of a genome. Through this rapid analysis, microarrays have dramatically accelerated research involving the human genome and proteome.
MYGN: 37.60 (+0.92)
Arrayit's Potential as a Blockbuster Companion Diagnostic
ACCESSWIRE-TNW - Thu Mar 07, 8:06AM CST
The pharmaceutical industry can be a volatile place to invest, with share prices relying on successful clinical trials and ongoing regulatory compliance. In many cases, companies could reduce these risks by properly vetting clinical trial participants and patients in order to ensure that they are treating the right patients. The personalized medicine movement could help in this regard with the growing popularity of so-called companion diagnostics.
Could Arrayit's Early Ovarian Cancer Diagnostic Save 12,000 Lives a Year?
ACCESSWIRE-TNW - Tue Feb 19, 8:06AM CST
The biotechnology industry is as exciting in 2013 as it ever has been before, providing investors opportunities to be a part of a paradigm shift that exploits decades of research that are now cornerstones for building game-changing therapies. One of the most intriguing propositions today is that of genomics, an industry that is gaining traction in the medical space in recent years. Ten years after the completion of the Human Genome Project, the decreasing costs associated with mapping and molecular diagnostics are shepherding increasing acceptance and usage, uniquely positioning Arrayit Corporation (OTCQB: ARYC) for growth amid larger peers like Exact Sciences Corp. (NASDAQ: EXAS) and Myriad Genetics, Inc. (NASDAQ: MYGN), especially with Arrayit's focus on diagnostics for ovarian cancer as part of their larger portfolio of offerings.
MYGN: 37.60 (+0.92), EXAS: 23.43 (-0.79)
